NCT04601051: Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM)
- State
- Completed
- Phase
- Phase 1
- People
- 72 taking part
- Started
- 5 Nov 2020
- Primary completion
- 12 Sep 2025
- Arms
- Polyneuropathy Part 1: NTLA-2001, Polyneuropathy Part 2: NTLA-2001, Cardiomyopathy Part 1 (UK only): NTLA-2001, Cardiomyopathy Part 2 (UK only): NTLA-2001, Polyneuropathy Follow-on Dosing (PN Part 1 Dose Level 1 Subjects only): NTLA-2001
- Results
- None posted
- 23 Oct 2020: Trial registered
- 5 Nov 2020: Trial started
- 12 Sep 2025: Trial completed